Chonnam Med J.  2015 Dec;51(3):109-114. 10.4068/cmj.2015.51.3.109.

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma

• Yang DH
• Jung SH
• Ahn JS
• Kim YK
• Min JJ
• Bom HS
• Lee JJ
• Kim HJ

• KMID: 2172126
• DOI: http://doi.org/10.4068/cmj.2015.51.3.109

Abstract

The prognostic value of whole-body positron emission tomography/computed tomography (PET/CT) with 18F-fluoro-2-deoxy-D-glucose (FDG) shortly after the onset of induction chemotherapy or mid treatment could help to predict long-term clinical outcomes in patients with Hodgkin's or Non-Hodgkin's lymphoma. However, FDG is not a tumor-specific substance, and it may accumulate to the point of being detected in a variety of benign conditions or at physiologic anatomical sites, which may give rise to false-positive interpretation. In an attempt to standardize the reporting criteria for interim PET/CT, the First International Workshop on Interim PET in Lymphoma suggested visual response criteria with the Deauville five-point scale, and the standardized uptake value (SUV) has been investigated in comparison with this visual system. A quantitative approach using the measurement of maximal SUV (SUVmax) or the reduction rate of SUVmax (DeltaSUVmax) might be more appropriate in early-response PET/CT for reducing false-positive rates or for decreasing interobserver variability in interpretation. In this review, the predictive efficacy of PET/CT is discussed for the treatment of aggressive lymphoma, especially in terms of an interim PET/CT-based prognostic model.

Keyword

Prognosis; Lymphoma; Non-Hodgkin; Positron-emission tomography

MeSH Terms

Education
Electrons*
Humans
Induction Chemotherapy
Lymphoma*
Lymphoma, Non-Hodgkin
Observer Variation
Positron-Emission Tomography
Positron-Emission Tomography and Computed Tomography
Prognosis

Reference

1. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001; 19:414–419.

2. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94:429–433.

3. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma. 2000; 39:543–553.

4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17:1244.

5. Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988; 6:1832–1837.

6. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989; 7:1018–1026.

7. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988; 6:931–933.

8. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002; 43:1018–1027.

9. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol. 2006; 85:759–767.

10. Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007; 48:1721–1727.

11. Zhao J, Qiao W, Wang C, Wang T, Xing Y. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Hematology. 2007; 12:423–430.

12. Fields PA, Mikhaeel G, Hutchings M, van der Walt J, Nunan T, Schey SA. The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. Haematologica. 2005; 90:1711–1713.

13. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106:1376–1381.

14. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005; 16:1514–1523.

15. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005; 16:1160–1168.

16. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107:52–59.

17. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET- scan in lymphoma. Leuk Lymphoma. 2009; 50:1257–1260.

18. Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010; 51:1857–1862.

19. Michallet AS, Trotman J, Tychyj-Pinel C. Role of early PET in the management of diffuse large B-cell lymphoma. Curr Opin Oncol. 2010; 22:414–418.

20. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangère T, Steinling M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010; 37:494–504.

21. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011; 73:332–337.

22. Wu X, Dastidar P, Pertovaara H, Korkola P, Järvenpää R, Rossi M, et al. Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET/CT. Mol Imaging Biol. 2011; 13:785–792.

23. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010; 51:2171–2180.

24. Rijbroek A, Boellaard R, Vriens EM, Lammertsma AA, Rauwerda JA. Comparison of transcranial Doppler ultrasonography and positron emission tomography using a three-dimensional template of the middle cerebral artery. Neurol Res. 2009; 31:52–59.

25. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys. 2007; 67:720–726.

26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329:987–994.

27. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937–1947.

28. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109:1857–1861.

29. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma. 2009; 50:1931–1936.

30. Castellucci P, Nanni C, Farsad M, Alinari L, Zinzani P, Stefoni V, et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun. 2005; 26:689–694.

31. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010; 28:1896–1903.

32. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009; 20:309–318.

33. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009; 50:527–533.

34. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48:1626–1632.

35. Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, et al. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011; 47:1312–1318.

36. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. Groupe d'étude des lymphomes de l'adulte (GELA).SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011; 118:37–43.

37. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003; 30:682–688.

38. Juweid ME, Smith B, Itti E, Meignan M. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? J Clin Oncol. 2010; 28:e719–e720. author reply e721-2.

39. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011; 52:386–392.

40. Horning SJ, Juweid ME, Schöder H, Wiseman G, McMillan A, Swinnen LJ, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010; 115:775–777. quiz 918.

41. Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013; 92:471–479.

42. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012; 87:511–519.

43. Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol. 2012; 157:159–170.

44. Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988; 6:1838–1844.

45. Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003; 14:881–893.

46. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003; 14:277–281.

47. Li YJ, Li ZM, Xia XY, Huang HQ, Xia ZJ, Lin TY, et al. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med. 2013; 54:507–515.

48. Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma. 2013; 54:2163–2167.

49. Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, et al. Prognostic significance of interim PET/CT based on visual, SUVbased, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015; 15:198.

50. Zinzani PL. PET in T-Cell Lymphoma. Curr Hematol Malig Rep. 2011; 6:241–244.

51. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007; 18:1685–1690.

52. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci. 2013; 104:1656–1661.